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A Pilot Placebo-Controlled Study of Chronic m-CPP 
Administration in Alzheimer's Disease 
Brian A. Lawlor, Trey Sunderland, Alan M. Mellow, 
Susan E. Molchan, Rick Martinez, and Dennis L. Murphy 
Meta-Chlorophenylpiperasine (m-CPP), a serotonin agonist and metabolite of the anti- 
depressant trazodone, was administered chronically to eight moderate to severely affected 
Alzheimer patients to determine whether it ~ prod._.~e improvement in behavioral 
symptoms complicating this illness. In doses ~ to 80 rag/day for 16 days, m-CPP was 
well tolerated and resulted in small but significant increases in anergy and depression- 
related symptoms compared with placebo. The effects of chronic m-CPP in this study 
contrast with the reported beneficial effects of the parent compound trazodone and se- 
lective 5-HT reuptake i~bitors in treating behavioral symptoms in AIzheimer patients. 
Introduction 
A number of recent studies have documented the existence of significant biochemical and 
neuroanatomic abnormalities in the serotonin (5-HT) system in Alzheimer's disease (AD) 
(Yamamoto and Hirano 1985; Bowen et al 1983; Cross et al 1984, 1986). The clinical 
correlates of 5-HT system dysfunction in AD is unknown, but altered 5-HT function may 
be implicated in the expression of behavioral and cognitive symptoms in this population. 
We have been using the 5-HT receptor agonist, meta-chlorophenylpiperazine (m-CPP), 
a metabolite of the heterocyclic antidepressant Irazodone, to examine the functional 
correlates of 5-HT abnormalities in AD. Although the pharmacological effects of m-CPP 
are varied and complex, m-CPP appears_ to act pri'mari_ly as a 5-__I-IT_ ._fete_ ~ r  agonist, with 
somewhat greater potency at the 5-HT,c than at the 5-HTn^ and 5-HTas sites (Schoeffter 
and Hoyer 1989). Because of the failure to demonstrate the existence of the 5-HTns 
receptor in human brain (Heuring et al 1986; Hoyer et al 1986), m-CPP's effects in 
humans cannot be attributed to agonist activity at the 5-HTm receptor site. 
In earlier studies, we established the safety of single-dose administration of m-CPP in 
an elderly neuropsychiatric population (Lawlor et al 1989a) and also found that AD 
patients showed increased behavioral responsivity to acute intravenous (IV) administration 
of this 5-HT agonist (Lawlor et al 1989b). Increased behavioral responsivity was not 
paralleled by any differences in neuroendocrine responsivity, suggesting that subpopu- 
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iations of 5-HT receptors remained functionally unaffected by the disease process. We 
postulated that the 5-HT receptors mediating certain aspects of behavior may be hyper- 
responsive in AD, and that a possible therapeutic sffategy could be to ~ g u l a t e  s ~ h  
a hyperresponsive receptor system by chronic lreatment with an agonist or with a 5-HT 
reuptake inhibitor. Furthermore, thecapeutic benefit was observed during chronic m-CPP 
administration in a small number of depressed patients (Mellow et al 1990). 
In this study, m-CPP was administered on a chronic ~ i s  to AD patients in a pilot 
double-blind, crossover study to determine whether it might be bbehav i~y  active 
whether direct agonist administration might produce behavioral or other ~wovement in 
this population. 
Methods 
Eight patient~ meeting strict NINCDS-ADRDA criteria for "probable A l ~ i mer ' s  dis- 
ease" (McKhann et al 1984) were entered into the study. All subjects were inpatients 
during the course of the study and were medically healthy as d e t e r m i ~  by physical 
examination and normal blood chemistries prior to beginning the study. ~ mean age 
of the patients was 68.0 _ 2.5 years, with a mean duration of f l ~ s s  of 5.8 _ 0.8 
years. All were moderately to severely affected, with ratings on the Global Deterio- 
ration Scale (GDS) (Reisberg et al 1982) and Clinical Dementia Rating Scale (CDR) 
(Hughes et al 1982) of 5.9 _+ 0.1 and 2.4 _+ 0.2, respectively. A l ~ g h  none of the 
p~tien~ ~ t  criteria for Major Depression on entry to the study, patients did have 
measurable levels of mild depression, as evidenced by b a s e l  ~ i o u - r e ~  
from the 17-item Dementia Mood Assessment Scale ( D ~ S )  ( S ~ r l a n d  et al 1988, 
1989) of 32.2 + 3 . 3 .  
Subjects received m-CPP or placebo in a double-bfind, placebo-conm3Hed, crossover 
fashion, randomized for order. Initial doses of m-CPP were 20 m~day, and m-CPP was 
increased in 20-rag increments over the fc!lowing 3-5 days to a ~ m u m  of 80 mR/day. 
Capsules were administered four times a ~My, at 9:00 AM, 1:00 PM, 6:00 PM, and 10:00 
PM. The duration of the placebo and active drug adminis~tion in ~ s  prefiminary study 
varied from patient to patient; the goal was to administer m-CPP for at least 2 weeks to 
each subject. At the completion of the drug treatment p ~ ,  ~ dose of m-CPP was 
nmv~ anu then d~sconunu¢~ completely ~e  following day. There was no was~u-t 
between active drug and placebo treatment phases. 
Behavioral measures included weekly ratings camed out by ~ n e d  raters blind to the 
treatment condition using the Brief Psychiatric Rating Scale 03PRS) ( O v e ~  and Gotham 
1962), modified Global Rating Scales (Bunney and Hamburg 1963), the DMAS, and 
nightly sleep checks documenting the number of hours of uninterrupted sleep. Patients 
also had blood drawn twice a week for routine hematology and biochemis~es (including 
liver function tests), m-CPP blood levels (drawn at 7:30 AM prior to the morning dose) 
were measured in five of the eight subjects at the end of the chro~c treatment phase. 
Data Analysis 
The group behavioral data were analyzed using paired t-tests c o ~ g  ~ BPRS, 
Global Ratings, and DMAS ratings at the end of drug and ~laccL'o t r e a ~ n ~ .  The sleep 
data were analyzed by repeated measures analysis of variance (ANOVA). All data are 
expressed as mean _ SEM, unless otherwise stated. 
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Table !. Behavioral Ratings in Eight Alzheimcr ~ ~ ~  m-Cl~ and 
Tlwmem Globei Global 
~ Gla la  ~ Gla ld  Olobei fmadmel oolJ ld~  
et ~ sex Due (deys) nee, s DM.~.I'7 d q m w e  **d~u m~ay ~ pro:bern impekum m p m n m  
I S7 M Placebo 17 43 21 2 6 4 ! 3 !0 9 
m-CIl~ t6 44 25 4 6 $ 2 ! I0 i0 
2 67 F Placebo 17 79 ~ 3 6 4 9 $ 14 I$ 
14 I I I  55 $ 7 9 13 4 I~ 13 
3 77 F ~ 16 42 2?. 3 4 6 4 I 15 14 
m-(~P 18 51 37 3 5 7 6 $ 14 14 
4 64 M Placebo II 64 2~ 3 6 6 4 I 9 iO 
m-CPP 20 81 33 2 4 8 6 I 9 9 
5 75 F Placcto 6 67 33 4 8 4 ! I 13 12 
m-CPl' 13 69 31 2 7 4 I 2 13 13 
6 65 F Placebo 12 c~ 46 7 9 9 9 7 14 14 
m-CPP 23 76 42 S 7 7 6 9 13 13 
7 75 F Placebo 8 67 49 4 $ 10 7 3 !0 I0 
m-El~ 7 72 62 4 6 !1 * 3 12 12 
8 64 M Placebo !1 56 28 $ 6 $ 4 ! I !  12 
18 66 42 6 8 $ $ 6 I I  I I  
qIPRS.  Brief Psychiatric Rating Scale4 DMAS, Dementia Mood Assessllleat Scale. ~ Ratings ( B u l m e y - H a n l b l ~ )  mage  from 
0.-15. 
Results  
m-CPP was tolerated by all subjects and no side effects related to drug treatment were 
reported or observed by the staff. There were no changes in blood indices during the 
course of the m-CPP trial that could be attributed to drug treatment. One female subject 
with x-ray evidence of osteoporogis at baseline ( ~ e n t  7, Table 11 ~ elevations of 
alkaline phosphatase (with normal SGOT and SGPT) while on m-CPP, but this was 
attributed to microfractures of the pelvis, as diagnosed by bone scan. 
The duration of active treatment for each individual patient is shown in Table 1. The 
mean daily dose of m-CPP was 55.3.4- 4.2 nag and the mean durations of m-CPP treatment 
and placebo were 16.13 _.+ 1.72 and 12.25 __. 1.46 days, respectively. The mean plasma 
m-CPP concentration (only available for five subjects) measured at the completion of the 
chronic treatment phase was 84.0 _.+ 42.0 ng/ml. 
Behavioral Ratings 
Individual scores on all behavioral scales for the eight patients following m-CPP and 
placebo are shown in Table 1. Five of eight patients showed increases in the DMAS and 
BPRS scores (indicating worsening in cfinical status) following m-CPP compared with 
placebo. There were no consistent changes along the individual "Global" items, in par- 
ticular across meas-mes of "cognitive" or "functional impairment.'" 
There was no difference between mean DMAS depression-related items at baseline 
(prior to drug cr placebo treatments) and DMAS following placebo (32.2 __. 3.3 versus 
32.6 _ 3.8), indicating that placebo treatment was not associated with any change in 
DMAS ratings. Following m-CPP, there were small but significant increases noted on 
the 17-item DMAS (32.6 +_. 3.8 versus 40.9 _.+ 4.4; p < 0.05), and on the "'vegetative" 
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factor of the DMAS (indicating decreased sleep, appetite, and energy) (1.0 -*- 0.3 versus 
1.9 _ 0.5; p < 0.001). Although t.hele was no overall significant change on ~ t ~  
24-item BPRS, there was a small but significant increase in the "aner~at" f ~  ( i n d i c ~ g  
increased emotional withdrawal, motor retardation, blunted affect, and disot'ientation) 
(3.1 _+ 0.5 versus 3.5 - 0.4; p < 0.001) following m-CPP compared with placebo. 
Sleep Records 
When mean nightly sleep records were compared, there was no overall difference between 
drug and placebo treatment conditions. However, consistent with ~ behavioral obser- 
vation in a number of patients, comparison of the immediate m-CPP withdrawal 
with the chronic m-CPP treatment phase revealed significantly decreased sleep during 
our nights following d:ug withdrawal compared with the chronic treatment ~ .  
Discussion 
hi this preliminary study, chronic m-CPP, in doses of up to 80 mg/day, was well tolerated 
and produced no significant changes in hematological or bioche~cal ~ c e s  in a group 
of moderate to severely affected AD subject, m-CPP tream,.ent did result m significant, 
albeit small, increases in depression-related items and anergy, but produced no significant 
change in cognitive function in this small group of severely impairaxi patients. Interest- 
ingly, in the only other reported clinical trial with chronic dosing of ~is agent, we found 
improvement in depressed mood in a subgroup of depressed patients following chronic 
m-CPP treatment (Mellow et ai 1990). One could postulate that ~ contrasting behavioral 
effects following m-CPP in these two populations could be e x p l ~  by the serotonergic 
(and other) neuronal losses in AD. However, it should be noted that the behavioral 
changes observed in this study were modest, and were found with a s ~  number of 
subjects. More definitive conclusions must await replication with larger patient numbers. 
In conclusion, chronic 5-I-11" agonist treatment with m-CPP produced small but sig- 
nificant increases in depression and anergy ratings in this group of moderate to severely 
affected AD patients. No beneficial or deleterious effects on cognition were observed m 
this small group of patients. The overall negative behavioral results in K s  p r e l i m i ~  
study conWast with the repor',~ -a ~ i t i v e  behavioral effects of 5-HT r e u ~  ~ b i f i o n  
in dementia populations (Nyth et al 1988), and of the effe r.s of the parent compound, 
trazodone, in agitated demented patients (Pinner and Rich 1988; Simpson and Foster 
1986). Future studies are warranted to explore whether 5-HT-selective agents (agonists 
or antagonists) are helpful in the management of noncognitive ~ cognitive symptoms 
inAD. 
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